Somaxon Pharmaceuticals (SOMX)
On June 4, 2009, Somaxon (SOMX - Analyst Report) announced that is has resubmitted the new drug application (NDA) to the U.S. FDA for Silenor (doxepin) for the treatment of insomnia. Despite this good news, we struggle to see how this drug can capture enough of the insomnia market to drive Somaxon to strong profitability.
The insomnia market is dominated by generic molecules, and without an onset claim, Silenor will already lose out on approximately half the market. Plus, Somaxon is running dangerously low on cash. We estimate the current cash balance is only enough to fund operations until July 2009.
Therefore, we expect a highly dilutive (30-40%) capital raise in the next week or two. We have a Sell rating on the shares and a target price of $0.50.
Somaxon Pharmaceuticals (SOMX) : FULL ANALYST REPORT
|
|
|
|
Share |
RSS |
Rate Pos |
Rate Neg |
Comment |
|
|
||||||
- Free Four Zacks #1 Rank "Strong Buy" Stocks
- Free Timely Market Commentary
- Free Wealth Management Tips
- Free Profitable Strategy Screens
- Free Bull and Bear Stocks of the Day
Loading Stories...Most Popular on Zacks.com
More Zacks Resources
More Zacks Links
| Market Summary | Feb 10, 2010 09:53 am ET |

Sponsored Links 
-2.52 %
[CLICK TO CLOSE X]
days
ago
[CLICK TO CLOSE X]
days
ago
[CLICK TO CLOSE X]
days
ago
[CLICK TO CLOSE X]